Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism

Definitions

• the present invention relates to an internal medicine.
• Oily components such as n-3 fatty acids such as docosahexaenoic acid and carotenoids have various physiological activities, and therefore, there is an increasing demand for dosage forms such as soft capsules as health foods.
• dosage forms such as soft capsules as health foods.
• n-3 fatty acids such as docosahexaenoic acid and carotenoids
• the stability of the content of the soft capsule cannot be maintained, and the components contained in the content tend to be separated.
• a method using a wax-based emulsifier or beeswax having a high thickening effect has been developed.
• this method has a problem that the dispersibility of the contents in water is poor in the disintegration test.
• Patent Documents 1 and 2 As a method for improving the dispersibility of the contents in water, a method of solubilizing with an emulsifier having a high HLB value is generally used (for example, Patent Documents 1 and 2). On the other hand, a method of dispersing a hardly oil-soluble powder with an emulsifier having a relatively low HLB value has been proposed (Patent Document 3).
• An object of the present invention is to provide an internal preparation that can exhibit a good balance between dispersibility and stability in an internal preparation containing two or more oily components.
• the present invention provides the following [1] to [10].
• Component (A) n-3 fatty acid
• Component (B) a crystalline oily component
• component (C) an internal preparation containing a glycerin fatty acid ester or polyglycerin fatty acid ester having an HLB of 5 or less.
• Component (D) The agent according to [1], further comprising a hydrophilic emulsifier having an HLB of 10 or more.
• Component (E) The agent according to [1] or [2], further comprising an emulsifier having an HLB of more than 5 and less than 10.
• the component (B) according to any one of [1] to [3], wherein the component (B) includes at least one selected from the group consisting of lutein, capsanthin, zeaxanthin, ⁇ -cryptoxanthin, and astaxanthin.
• Agent [5] The agent according to any one of [1] to [4], wherein the content of component (B) is 0.2% by mass or more based on the total amount of the composition.
• [6] The agent according to any one of [1] to [5], wherein the content of component (A) is 60% by mass or less based on the total amount of the composition.
• component (A) is docosahexaenoic acid.
• an internal preparation that can exhibit the dispersibility and stability of the components (A) and (B) in a balanced manner is provided.
• the internal preparation of the present invention contains the following component (A): n-3 fatty acid.
• the n-3 fatty acid is a fatty acid having an unsaturated bond at the third (n3-position, ⁇ 3-position) carbon-carbon bond from the methyl end of the fatty acid.
• the origin of the n-3 fatty acid is not particularly limited, and may be naturally derived from plants, animals, microorganisms, etc., may be artificially produced such as chemical synthesis, or biotechnology such as genetic recombination It may be manufactured by or a commercially available product.
• the number of carbon atoms contained in the fatty acid is usually 15 or more, preferably 17 or more, and more preferably 19 or more.
• the upper limit of the number of carbon atoms is usually 30 or less, and preferably 25 or less.
• n-3 fatty acids include docosahexaenoic acid (DHA, (4Z, 7Z, 10Z, 13Z, 16Z, 19Z) -docosa-4,7,10,13,16,19-hexaenoic acid), docosapentaenoic acid (DPA, all-cis-docosa-7,10,13,16,19-pentaenoic acid), ⁇ -linolenic acid, eicosatetraenoic acid (ETA, all-cis-8,11,14,17-eicosa) Tetraenoic acid) and eicosapentaenoic acid (EPA, (5Z, 8Z, 11Z, 14Z, 17Z) -icosa-5,8,11,14,17-pentaenoic acid).
• the n-3 fatty acid is preferably a component (functional component) capable of exerting physiological functions in the body of an organism, and more preferably DHA.
• DHA is often derived from natural products such as animals (for example, fish) and microorganisms (for example, Schizophytrium genus microorganisms), but is not limited thereto. DHA may be in the form of a pharmacologically acceptable salt.
• DHA may be DHA as a free fatty acid or a derivative thereof.
• the derivative include triglyceride type DHA (TG-DHA) and phospholipid type DHA.
• TG-DHA is a compound in which triglycerol and DHA are ester-bonded. DHA as one or more fatty acids per molecule of triglycerol can bind.
• TG-DHA preferably has two or more DHA molecules bound to one molecule of triglycerol.
• the phospholipid type DHA is a compound in which DHA is bound to a phospholipid such as phosphatidylcholine and phosphatidylserine.
• Component (A) may be a single n-3 fatty acid or a combination of two or more n-3 fatty acids.
• the content of the component (A) is usually 15% by mass or more, preferably 18% by mass, more preferably 20% by mass or more, and further preferably 25% by mass or more with respect to the total amount of the composition.
• the upper limit is usually 65% by mass or less, preferably 60% by mass or less, more preferably 55% by mass or less, and still more preferably 50% by mass or less.
• the internal preparation of this invention can become an agent excellent in balance of stability and a dispersibility.
• the content of the component (A) is usually 15 to 65% by mass, preferably 15 to 60% by mass, more preferably 18 to 55% by mass, and further preferably 20 to 55% by mass with respect to the entire composition. %, Even more preferably 25 to 50% by weight.
• the internal preparation of this invention can exhibit the physiological function of a component (A) efficiently, and can become an agent excellent in balance of stability and a dispersibility.
• the internal preparation of the present invention contains component (B): a crystalline oily component.
• Crystalline oily component means a component that is crystalline and insoluble in water. Insoluble in water means, for example, when the sample is dissolved in 100 g of water (20 ° C.), the solubility is less than 0.1 g / 100 g of water.
• the crystalline oily component does not contain n-3 fatty acids.
• the origin of the crystalline oily component is not particularly limited, and it may be naturally derived from plants, animals, microorganisms, etc., may be artificially produced such as chemical synthesis, or by biotechnology such as genetic recombination. What was manufactured may be sufficient and a commercial item may be sufficient.
• the crystalline oily component examples include carotenoids, ubiquinones (such as coenzyme Q10), fat-soluble vitamins (such as vitamin E (such as tocopherol and tocotrienol)), vitamin K, and sterols (such as squalane), and carotenoids are preferred.
• Carotenoids are usually contained as pigments in animals and plants and have a polyene structure consisting of conjugated double bonds.
• the carotenoid preferably contains an oxygen atom, and more preferably contains a hydroxyl group (—OH).
• the number of carbon atoms in the carotenoid is usually 20 or more, preferably 25 or more, more preferably 30 or more, and further preferably 40 or more. It is preferable that the carotenoid can exhibit a physiological function (has functionality) in the body of an organism.
• carotenoids examples include lutein ( ⁇ , ⁇ -carotene-3,3′-diol; C 40 H 56 O 2 ), capsanthin (all-trans-capsanthin, (3R, 3 ′S, 5′R) -3, 3′-dihydroxy- ⁇ , ⁇ -carotene-6′-one; C 40 H 56 O 3 ), zeaxanthin (4- [18- (4-hydroxy-2,6,6-trimethyl-1-cyclohexenyl)- 3,7,12,16-tetramethyl-octadeca-1,3,5,7,9,11,13,15,17-nonaenyl] -3,5,5-trimethyl-3-cyclohexen-1-ol; C 40 H 56 O 2 ), ⁇ -cryptoxanthin ((R) -3,5,5-trimethyl-4- [3,7,12,16-tetramethyl-18- (2,6,6-trimethylcyclohexene) Sa-1-e Le) -
• Lutein is present in the chloroplasts of higher plants (spinach, kale, komatsuna, etc.).
• Capsanthin is present in plants such as paprika and capsicum.
• Zeaxanthin is present in plants (such as corn), egg yolk, and animal fat.
• ⁇ -cryptoxanthin is present in plants such as Satsuma mandarin, physalis, orange, papaya, and apple, dairy products such as egg yolk and butter, and animals such as cows.
• Astaxanthin is present in crustaceans such as shrimps and crabs, and fish such as salmon and red sea bream.
• each carotenoid is not limited to those derived from these. Each carotenoid may be in the form of a pharmacologically acceptable salt.
• Component (B) may be one type of crystalline oily component or a combination of two or more types of crystalline oily components.
• component (B) contains two or more kinds of carotenoids, it preferably contains a combination of lutein and capsanthin, a combination of lutein, capsanthin and zeaxanthin, and a combination of lutein and capsanthin or a combination of lutein, capsanthin and zeaxanthin. More preferred.
• the content of the component (B) is usually 0.01% by mass or more, preferably 0.1% by mass or more, more preferably 0.2% by mass or more with respect to the total amount of the composition.
• the internal preparation of this invention can exhibit the physiological function of a component (B) efficiently.
• the upper limit is usually 10% by mass or less, preferably 8% by mass or less, more preferably 4% by mass or less, and still more preferably 3% by mass or less.
• the stability of the internal preparation of the present invention can be improved, and the internal preparation of the present invention can be an agent having an excellent balance between stability and dispersibility.
• the content of component (B) is usually 0.01 to 10% by weight, preferably 0.1 to 8% by weight, more preferably 0.2 to 4% by weight, based on the entire composition.
• the content is preferably 0.2 to 3% by mass.
• the internal preparation of the present invention contains component (C): glycerin fatty acid ester or polyglycerin fatty acid ester having an HLB of 5 or less.
• the HLB of glycerin fatty acid ester and polyglycerin fatty acid ester as component (C) is usually 5 or less, preferably 4.7 or less, more preferably 4.5 or less. Thereby, the stability of the component (A) and the component (B) in the internal medicine can be improved.
• the minimum of HLB is not specifically limited, Usually, it is 0 or more. Therefore, the HLB of component (C) is usually 0 to 5, preferably 0 to 4.7, more preferably 0 to 4.5.
• HLB Hydrophilicity
• Glycerin fatty acid ester is a fatty acid ester-bonded to at least one of the hydroxyl groups of glycerin.
• each fatty acid may be the same as or different from each other.
• the number of carbon atoms of the fatty acid contained in the glycerin fatty acid ester is usually 8 or more, preferably 14 or more.
• the upper limit is usually 22 or less, preferably 18 or less.
• the number of carbon atoms is preferably 8 to 22, more preferably 8 to 18, and still more preferably 14 to 18.
• the fatty acid may be either an unsaturated fatty acid or a saturated fatty acid.
• fatty acids possessed by glycerin fatty acid esters include caprylic acid, pelargonic acid, capric acid, lauric acid, pentadecylic acid, myristic acid, palmitic acid, margaric acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and behenic acid.
• Acid erucic acid, caprylic acid, pelargonic acid, capric acid, lauric acid, pentadecylic acid, myristic acid, palmitic acid, margaric acid, stearic acid, oleic acid, linoleic acid, linolenic acid are preferred, palmitic acid, margarine Acid and stearic acid are more preferable.
• Polyglycerin fatty acid ester is a fatty acid esterified with at least one of the hydroxyl groups of polyglycerol which is a polymer of glycerin.
• the degree of polymerization of polyglycerol is usually 6 or less, preferably 5 or less, more preferably 4 or less.
• the lower limit is usually 2 or more.
• the degree of polymerization of polyglycerol is preferably 2 to 6, more preferably 2 to 5, and still more preferably 2 to 4.
• each fatty acid may be the same as or different from each other.
• the preferable example of the fatty acid which polyglycerin fatty acid ester has it is the same as that of mentioning about the fatty acid which glycerin fatty acid ester has.
• the component (C) may be one kind selected from glycerin fatty acid ester and polyglycerin fatty acid ester having an HLB of 5 or less, or a combination of two or more kinds, but preferably contains at least a glycerin fatty acid ester having an HLB of 5 or less. More preferably, the HLB is 5 or less glycerin fatty acid ester.
• the content of the component (C) is usually 1% by mass or more, preferably 2% by mass or more, more preferably 3% by mass or more, and further preferably 4% by mass or more with respect to the total amount of the composition.
• the upper limit is usually 20% by mass or less, preferably 15% by mass or less, more preferably 10% by mass or less, and still more preferably 8% by mass or less. Therefore, the content of the component (C) is usually 1 to 20% by mass, preferably 2 to 15% by mass, more preferably 3 to 10% by mass, and further preferably 4 to 8% by mass with respect to the entire composition. %is there.
• the internal use preparation of this invention can improve stability, and can be made into an agent which does not have a problem also in the safety
• the internal preparation of the present invention may contain a component (D): a hydrophilic emulsifier having an HLB of 10 or more, and preferably contains a component (D).
• a component (D) a hydrophilic emulsifier having an HLB of 10 or more, and preferably contains a component (D).
• the hydrophilic emulsifier may be an emulsifier exhibiting hydrophilicity
• the HLB is usually 10 or more, preferably 12 or more, more preferably 14 or more, and further preferably 15 or more.
• stability of the component (A) and component (B) in an internal use can be improved more.
• the upper limit of HLB is not specifically limited, Usually, it is 20 or less. Therefore, the HLB of component (D) is usually 10 to 20, preferably 12 to 20, more preferably 14 to 20, and still more preferably 15 to 20.
• hydrophilic emulsifiers include nonionic surfactants.
• Nonionic surfactants include sucrose fatty acid ester, polyglycerin fatty acid ester, organic acid monoglyceride, propylene glycol fatty acid ester, polyglycerin condensed ricinoleic acid ester, sorbitan fatty acid ester, and polyoxyethylene sorbitan fatty acid ester.
• Sugar fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters are preferred, and polyglycerin fatty acid esters, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters are more preferred.
• Sucrose fatty acid ester is a fatty acid ester-bonded to at least one of the hydroxy groups of sucrose.
• each fatty acid may be the same as or different from each other.
• the number of carbon atoms of the fatty acid contained in the sucrose fatty acid ester is usually 8 or more, preferably 12 or more, more preferably 14 or more.
• the upper limit is usually 22 or less, preferably 20 or less, more preferably 16 or less.
• the number of carbon atoms is preferably 8 to 22, more preferably 12 to 20, and still more preferably 14 to 16.
• the fatty acid may be either an unsaturated fatty acid or a saturated fatty acid.
• fatty acids possessed by sucrose fatty acid esters include caprylic acid, pelargonic acid, capric acid, lauric acid, pentadecylic acid, myristic acid, palmitic acid, margaric acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, Examples include behenic acid and erucic acid, lauric acid, pentadecylic acid, myristic acid, palmitic acid, margaric acid, stearic acid, oleic acid, linoleic acid, and linolenic acid are preferable, and palmitic acid, margaric acid, and stearic acid are more preferable.
• sucrose fatty acid esters examples include sucrose dioleate, sucrose distearate, sucrose dipalmitate, sucrose dimyristate, sucrose dilaurate, sucrose monooleate, sucrose mono Examples include stearic acid ester, sucrose monopalmitic acid ester, sucrose monomyristic acid ester, and sucrose monolauric acid ester.
• the polyglycerin fatty acid ester as the component (D) may be any polyglycerin fatty acid ester other than the polyglycerin fatty acid ester as the component (C).
• the degree of polymerization of polyglycerol is usually 7 or more, preferably 8 or more.
• the upper limit is usually 15 or less, preferably 10 or less.
• the degree of polymerization of polyglycerol is preferably 7 to 15, and more preferably 8 to 10.
• each fatty acid may be the same as or different from each other.
• the preferable example of the fatty acid which polyglycerin fatty acid ester has it is the same as that of the fatty acid which glycerin fatty acid ester as a component (C) has.
• Sorbitan fatty acid ester is a fatty acid ester-bonded to at least one of the hydroxy groups of sorbitan.
• each fatty acid may be the same as or different from each other.
• Preferable examples of the fatty acid that the sorbitan fatty acid ester has are the same as those mentioned for the fatty acid that the sucrose fatty acid ester has.
• Polyoxyethylene sorbitan fatty acid ester is one in which ethylene oxide is ester-bonded to at least one of the hydroxy groups of sorbitan fatty acid ester. Preferred examples of the sorbitan fatty acid ester are the same as described above.
• the number of moles of ethylene oxide added to the polyoxyethylene sorbitan fatty acid ester is usually 2 or more, preferably 4 or more, more preferably 10 or more.
• the upper limit is usually 100 or less, preferably 50 or less, more preferably 30 or less.
• the added mole number is preferably 2 to 100, more preferably 4 to 50, and still more preferably 10 to 30.
• Component (D) may be one type selected from hydrophilic emulsifiers, or a combination of two or more types.
• the content of the component (D) is usually 0.1% by mass or more, preferably 0.2% by mass or more, more preferably 0. It is 3% by mass or more, more preferably 0.5% by mass or more.
• the upper limit is usually 5% by mass or less, preferably 3% by mass or less, more preferably 2.5% by mass or less, and further preferably 2% by mass or less. Therefore, the content of component (D) is usually 0.1 to 5% by mass, preferably 0.2 to 3% by mass, more preferably 0.3 to 2.5% by mass, based on the entire composition. More preferably, it is 0.5 to 2% by mass.
• the internal preparation of this invention is excellent in balance of stability and dispersibility, and can be made into an agent which does not have a problem also in the safety as a foodstuff.
• the internal preparation of the present invention may contain an emulsifier having an ingredient (E): HLB of more than 5 and less than 10, and preferably contains an ingredient (E).
• an emulsifier having an ingredient (E): HLB of more than 5 and less than 10, and preferably contains an ingredient (E).
• the HLB of the emulsifier as the component (E) exceeds 5, preferably 5.5 or more, more preferably 6.0 or more.
• the upper limit is usually less than 10, preferably 9.7 or less, more preferably 9.3 or less.
• the HLB is usually more than 5 and less than 10, preferably 5.5 to 9.7, more preferably 6.0 to 9.3.
• Component (E) may be an emulsifier having an HLB exceeding 5 and less than 10, but from the group consisting of glycerin fatty acid ester, polyglycerin fatty acid ester, organic acid monoglyceride, sorbitan fatty acid ester, and polyoxyethylene sorbitan fatty acid ester. It is preferable that at least one selected.
• the glycerin fatty acid ester as the component (E) may be a glycerin fatty acid ester other than the glycerin fatty acid ester as the component (C) and the component (D).
• glycerol fatty acid ester it is the same as that of mentioning in the glycerol fatty acid ester as a component (C) and a component (D).
• the polyglycerin fatty acid ester as the component (E) may be any polyglycerin fatty acid ester other than the polyglycerin fatty acid ester as the component (C) and the component (D).
• a polyglycerol fatty acid ester it is the same as that of mentioning in the polyglycerol fatty acid ester as a component (C) and a component (D).
• Organic acid monoglyceride is a compound in which the —OH group at the 3-position of glycerin fatty acid monoester is esterified with an organic acid.
• the number of carbon atoms of the fatty acid contained in the organic acid monoglyceride is usually 8 or more, preferably 14 or more.
• the upper limit is usually 22 or less, preferably 18 or less.
• the number of carbon atoms is preferably 8 to 22, more preferably 8 to 18, and still more preferably 14 to 18.
• the fatty acid may be either an unsaturated fatty acid or a saturated fatty acid.
• fatty acids possessed by glycerin fatty acid esters include caprylic acid, pelargonic acid, capric acid, lauric acid, pentadecylic acid, myristic acid, palmitic acid, margaric acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, and behenic acid.
• acids such as caprylic acid, pelargonic acid, capric acid, lauric acid, pentadecylic acid, myristic acid, palmitic acid, margaric acid, stearic acid, oleic acid, linoleic acid, and linolenic acid, and palmitic acid, margaric acid, stearin Acid is more preferred.
• Examples of the organic acid that the organic acid monoglyceride has include oxycarboxylic acids such as tartaric acid, lactic acid, malic acid, citric acid, and diacetyltartaric acid; aliphatic saturated dicarboxylic acids such as succinic acid, oxalic acid, adipic acid, and glutaric acid; Monocarboxylic acids composed of lower fatty acids such as propionic acid and butyric acid; aliphatic unsaturated dicarboxylic acids such as maleic acid and fumaric acid; and amino acids such as glycine and aspartic acid; oxycarboxylic acids and aliphatic saturated dicarboxylic acids An acid is preferable, and diacetyltartaric acid, lactic acid, citric acid, and succinic acid are more preferable.
• oxycarboxylic acids such as tartaric acid, lactic acid, malic acid, citric acid, and diacetyltartaric acid
• citric acid monoglyceride For example,
• the sorbitan fatty acid ester as the component (E) may be a sorbitan fatty acid ester other than the sorbitan fatty acid ester as the component (D).
• sorbitan fatty acid ester it is the same as that of mentioning in the glycerol fatty acid ester as a component (D).
• Component (E) may be one type selected from glycerin fatty acid esters having an HLB exceeding 5 and less than 10, or a combination of two or more.
• the content of the component (E) is usually 0.5% by mass or more, preferably 1% by mass or more, more preferably 2% by mass or more based on the total amount of the composition. More preferably, it is 3% by mass or more, and still more preferably 4% by mass or more.
• the upper limit is usually 20% by mass or less, preferably 18% by mass or less, more preferably 15% by mass or less, and still more preferably 10% by mass or less. Therefore, the content of component (E) is usually 0.5 to 20% by mass, preferably 1 to 18% by mass, more preferably 2 to 15% by mass, and further preferably 3 to It is 10% by mass, and more preferably 4 to 10% by mass.
• the agent of this invention can improve the stability and / or dispersibility of an internal use agent.
• the ratio of the content of the component (B) to the content of the component (A) ((B) / (A)) (%) is preferably more than 0%, more preferably 0.5% or more. Although there is no upper limit in particular, it is usually 10.0% or less.
• the ratio ((C) / ((A) + (B)) (%) of the content of component (C) to the total content of component (A) and component (B) is usually 3% or more.
• the upper limit is not particularly limited, but is usually 40% or less, preferably 30% or less, whereby the stability of the internal use can be further improved.
• the ratio of the content of the component (B) to the total content of the component (C) and the component (D) ((B) / ((C) + (D)) ( %) Is usually at least 3%, preferably at least 4%, although there is no particular upper limit, it is usually at most 70%, preferably at most 60%, more preferably at most 50%.
• the stability and / or dispersibility of the component (A) and the component (B) in the internal medicine can be further improved.
• the ratio of the content of the component (D) to the content of the component (C) ((D) / (C)) (%) is usually 70% or less, 60% Or less, more preferably 50% or less, still more preferably 40% or less, and even more preferably 30% or less. There is no particular lower limit, usually exceeding 0%, preferably 5% or more, more preferably 8% or more, and even more preferably 10% or more. Thereby, the stability and / or dispersibility of the component (A) and the component (B) in the internal medicine can be further improved.
• the ratio of the content of component (D) to the total content of component (C) and component (E) ((D) / ((C) + (E))) (%) is preferably 40% or less, and more preferably 30% or less. There is no particular lower limit, and it is usually sufficient to exceed 0%. Thereby, the stability and / or dispersibility of the component (A) and the component (B) in the internal medicine can be further improved.
• the internal preparation may contain an emulsifier other than Component (F): Components (A) to (E).
• Examples of the pharmacologically acceptable salt in the present invention include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate and phosphate; Organic acid salts such as acid salts, acetate salts, formates, propionates, benzoates, trifluoroacetates, maleates, tartrates, methanesulfonates, benzenesulfonates, paratoluenesulfonates; Inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt and ammonium salt; organic base salts such as triethylammonium salt, triethanolammonium salt, pyridinium salt and diisopropylammonium salt; amino acids such as arginine, aspartic acid and glutamic acid Salt.
• inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate and phosphate
• the internal preparation of the present invention may further have components other than those described above and a pharmacologically acceptable base.
• a pharmacologically acceptable base is a component that mainly ensures stability in storage and distribution (for example, a storage stabilizer).
• one or two or more types of components preferably about 1 to 3 types, more preferably about 1 type selected from various components constituting the target final product (for example, foods and drinks, pharmaceuticals, quasi drugs, etc.) ) May be contained.
• the pharmacologically acceptable base is not particularly limited as long as the object of the present invention is not impaired.
• strengthening agents, vitamins, swelling agents, thickeners, surfactants, etc. which do not impair various properties required for the formulation (eg, formulation stability) 1 type, or 2 or more types can be selected according to the dosage form.
• the pharmacologically acceptable base may be another component having an inhibitory effect on nitric oxide production.
• oils and fats examples include fatty acid esters other than components (A) to (F), edible oils and fats, hydrocarbons, higher fatty acids, and higher alcohols, and edible oils and fats are preferred.
• fatty acid esters other than components (A) to (F) include fatty acid esters other than components (A) to (F), edible oils and fats, hydrocarbons, higher fatty acids, and higher alcohols, and edible oils and fats are preferred.
• the ratio of the total amount of components (A) to (F) (components (D) to (F) is optional) to the total amount of oil component and components (A) to (F) is: Usually, it is 3% by mass or more, preferably 4% by mass or more. The upper limit is usually 90% by mass or less, preferably 80% by mass or less.
• excipient examples include cellulose such as hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, crystalline cellulose, ethylcellulose, low-substituted hydroxypropylcellulose, and pharmacologically acceptable derivatives thereof; polyvinylpyrrolidone, partially saponified polyvinyl alcohol Synthetic polymers such as gelatin, gum arabic powder, pullulan, agar, alginic acid, sodium alginate, chitansan gum, etc .; ethanol, glycerin, isobutyl alcohol, isopropyl alcohol, butanol, propanol, 2-pentanol, 2-methylbutanol Lower alcohols such as 3-methyl-2-butanol, 3-methyl-2-butenol, 1-penten-3-ol; hydrogenated rapeseed oil alcohol, laur Higher alcohols such as alcohol, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, lanolin alcohol, octyl
• disintegrant examples include crospovidone, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl starch sodium, hydroxypropyl starch, and partially pregelatinized starch.
• binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, dextrin, starch, and pregelatinized starch.
• the lubricant examples include calcium stearate, magnesium stearate, sucrose fatty acid esters other than component (D) and component (E), light anhydrous silicic acid, sodium stearyl fumarate, polyethylene glycol, talc, and stearic acid. It is done.
• the content of the lubricant with respect to the total amount of the agent is preferably 0.01% by mass or more.
• the upper limit is preferably 25% by mass or less.
• colorant examples include caramel dye, turmeric dye, orange dye, cacao dye, red pepper dye, marigold dye, iron (III) oxide, titanium dioxide, safflower dye, gardenia dye, and copper chlorophyll dye.
• Examples of the internal preparation of the present invention include agents used in oral administration forms (for example, oral administration, sublingual administration). Among these, a less invasive dosage form is preferable, and oral administration (internal use) is more preferable.
• Examples of the dosage form of the oral administration agent (internal use) or the composition for oral administration (composition for internal use) include, for example, liquid (solution), syrup (syrup), tablet (tablet, tablet), capsule (capsule) Agent), powder (granule, fine granule), soft capsule (soft capsule), solid, semi-liquid, cream, and paste.
• the administration target of the internal preparation may be an animal including a human, and is usually a human, but an animal other than a human (eg, mouse, rat, hamster, dog, cat, sheep, goat, cow, pig, monkey, etc. Mammals).
• the internal preparation of the present invention can be used as a food composition, medicine, or quasi drug.
• food compositions include beverages (soft drinks, carbonated drinks, nutritional drinks, powdered drinks, fruit drinks, milk drinks, jelly drinks, etc.), confectionery (cookies, cakes, gums, candies, tablets, gummies, buns, sheep candy) , Pudding, jelly, ice cream, sherbet, etc.), processed fishery products (kamaboko, chikuwa, hanpen, etc.), processed livestock products (hamburg, ham, sausage, winner, cheese, butter, yogurt, fresh cream, cheese, margarine, fermentation Milk, etc.), soup (powder soup, liquid soup, etc.), staple foods (rice, noodles (dried noodles, raw noodles), bread, cereals, etc.), seasonings (mayonnaise, shortening, dressing, sauce, sauce, soy sauce, etc.) ).
• the dosage form of the internal preparation of the present invention is usually oral administration such as buccal administration and sublingual administration.
• the dosage form of the internal preparation of the present invention can be determined as appropriate depending on whether it is a food or drink, a drug, or a quasi drug, and is not particularly limited.
• dosage forms for oral administration are liquid (liquid), syrup (syrup), tablet, capsule (capsule), powder (granular (granule), fine (powder)) , Soft capsules (soft capsules), solids (solid preparations), semi-liquids, creams, and pastes, with soft capsules (soft capsules) being preferred.
• the method for producing the internal preparation is not particularly limited, and may be followed according to a conventional method based on the dosage form and use. As an example, a production method when the dosage form is a soft capsule is shown below.
• Heating is usually performed at 40 ° C. or higher, preferably 50 ° C. or higher, more preferably 55 ° C. or higher. Although there is no particular upper limit, it is usually 100 ° C. or lower, preferably 90 ° C. or lower, more preferably 80 ° C. or lower. Therefore, the heating is usually performed at 40 to 100 ° C., preferably 50 to 90 ° C., more preferably 55 to 80 ° C.
• the mixing is preferably performed so as to be uniform, and stirred as necessary.
• the cooling temperature is usually 70 ° C.
• the cooling temperature is usually 20 to 70 ° C., preferably 22 to 60 ° C., more preferably 25 to 40 ° C.
• component (B) is added and mixed (preferably so as to be uniform, and stirred as necessary) to obtain the contents of the soft capsule (hereinafter also referred to as “content liquid”).
• Content liquid contains the contents of the soft capsule (hereinafter also referred to as “content liquid”).
• Mixing is preferably performed mechanically.
• the apparatus is not particularly limited, and examples thereof include a high-speed stirrer such as a homomixer and a high-pressure homogenizer, and a high-pressure pulverizer.
• the obtained content liquid is included in the coating substrate.
• the inclusion method include a flat plate method and a rotary die method. The latter is taken as an example, assuming that a medicine tank and a gelatin melting tank are provided, and a filling machine capable of setting a die roll and a tumbler dryer are used. Explained.
• a film substrate for example, a polymer such as gelatin or starch
• a plasticizer for example, glycerin, sorbitol, etc.
• purified water or the like
• a small tank usually warming (50 to 55 ° C)
• the drying temperature is usually 20 to 30 ° C. and the relative humidity is 30 to 50%.
• the drying time is usually 24 to 48 hours. For example, when the water content at the time of filling is 30 to 40%, the drying is performed until the water content decreases to 6 to 8%.
• the dried soft capsules may be polished with a tumbler for 2 minutes to 1 hour, if necessary, to finish the soft capsules.
• the oral preparations of the present invention are foods such as health foods, functional foods, dietary supplements (supplements), foods for specified health use, medical foods, foods for the sick, foods for infants, foods for nursing care, foods for the elderly, etc. It can be used as a medicine or quasi-drug.
• Examples 1 to 46 and Comparative Examples 1 to 3 The contents of soft capsules prepared with the compositions described in Tables 1 to 7 were subjected to the following evaluation tests.
• the soft capsule was prepared according to a conventional method. That is, after mixing each component as the contents, each component as a film was coated to obtain a soft capsule.
• One of the evaluation of separation of the soft capsule content liquid and the evaluation of dispersibility in water in each of the examples and comparative examples is that one is B or more and the other is C or more, or both are C or more. It can be evaluated that it is suitable as a formulation by the above.
• Tables 1-7 The results of the evaluation test are shown in Tables 1-7.
• Table 8 shows information on the components used in each example and comparative example.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Hematology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=62242359

Family Applications (1)

Country Status (5)

Cited By (1)

Citations (6)

Family Cites Families (4)

• 2017
  • 2017-11-28 TW TW106141400A patent/TW201821066A/zh unknown
  • 2017-11-28 JP JP2018554163A patent/JP7133471B2/ja active Active
  • 2017-11-28 KR KR1020197004344A patent/KR20190089149A/ko not_active Application Discontinuation
  • 2017-11-28 WO PCT/JP2017/042649 patent/WO2018101269A1/ja active Application Filing
  • 2017-11-28 CN CN201780071061.9A patent/CN109963558A/zh active Pending

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events